Qlife reaches production milestone – Signs outsourcing agreement with Finnish Scanfil

Qlife has signed an outsourcing agreement with Finnish group Scanfil to take over the continued production of the company’s Egoo device. Scanfil is a world leader in manufacturing and a system supplier to the global electronics industry with a vast network of factories, including a factory in Åtvidaberg, Sweden, that will support Qlife.

“The new agreement with Scanfil is a milestone for Qlife. As part of our long-term strategy, we initiated the outsourcing a while ago, and we expect the cooperation to give us both a better flexibility towards the market and a positive effect on our costs”, says Thomas Warthoe, CEO of Qlife Holding.

In line with the company’s overall business plan, Qlife initiated an outsourcing cooperation with Scanfil during the second quarter of 2021 with the aim to move out all device manufacturing by mid 2022. The target is to reach a capacity of 1,000 devices per month in 2023 to support our roll-out and go-to-market plans, and eventually scale to volumes that can service consumer markets.

“We are very satisfied with the cooperation with Scanfil. The company is a well-known manufacturer, and we trust that choosing a solid partner will benefit our potential for long-term growth. Scanfil has the know-how and the network to provide us with security in terms of scale, pricing, and global supply”, says Thomas Warthoe, CEO of Qlife Holding.

About Scanfil

Scanfil is a publicly traded Finnish company listed at Nasdaq Finland Ltd. The company is an established international manufacturing partner and system supplier for the international electronics industry. Scanfil has nine factories in seven countries across the globe. For more information see www.scanfil.com

For more information please contact:

Thomas Warthoe, CEO
tw@egoo.health
+45 21 63 35 34

Qlife is a medical device company that seeks to revolutionize the clinical biomarker market for whole blood testing by taking it out of the lab and into the homes. This will facilitate easy access to blood sample results and in turn facilitate increased monitoring of parameters that enables care improvement.

Shares for Qlife are being traded on Nasdaq First North Growth Market in Stockholm with G&W Fondkommission as certified advisor (phone: +46 (0) 8-503 000 50, e-mail: ca@gwkapital.se).
Read more on Egoo.health, Qlifeholding.com or follow us on LinkedIn.